Financial Performance - The company reported a basic earnings per share of -2.73 yuan for 2024, an improvement of 2.5% compared to -2.80 yuan in 2023 [1] - The net profit for 2024 was -1.468 billion yuan, showing a slight improvement of 2.85% from -1.511 billion yuan in 2023 [1] - The operating revenue increased significantly by 58.54% to 1.717 billion yuan in 2024, compared to 1.083 billion yuan in 2023 [1] - The return on equity was -54.07% in 2024, worsening from -35.52% in 2023 [1] - The net asset per share decreased by 42.25% to 3.65 yuan in 2024 from 6.32 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 24.03406 million shares, accounting for 68.36% of the circulating shares, with a change of 914,400 shares from the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 18.95667 million shares, representing 53.93% of the total share capital [3] - New entrants to the top ten shareholders include China Minsheng Bank's fund and a new investment fund from China Bank, while E Fund's healthcare fund and Shanghai Liyi Investment Management have exited the top ten [3] Dividend Distribution - The company has announced no dividend distribution or capital increase for the current period [4]
荣昌生物:2024年报净利润-14.68亿 同比增长2.85%